| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| General and administrative | 1,056,560 | 1,242,340 | ||
| Research and development | 2,196,828 | 1,167,045 | ||
| Total operating expenses | 3,253,388 | 2,409,385 | ||
| Loss from operations | -3,253,388 | -2,409,385 | ||
| Interest income | 37,023 | 38,609 | ||
| Interest expense | 2,116 | 4,185 | ||
| Total other income (expense) | 34,907 | 34,424 | ||
| Net loss | -3,218,481 | -2,374,961 | ||
| Loss per share - basic | -5.76 | -6.42 | ||
| Loss per share - diluted | -5.76 | -6.42 | ||
| Weighted average shares outstanding - basic | 558,868 | 370,127 | ||
| Weighted average shares outstanding - diluted | 558,868 | 370,127 | ||
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)